医学
索拉非尼
贝伐单抗
阿替唑单抗
肿瘤科
肝细胞癌
伦瓦提尼
内科学
靶向治疗
瑞戈非尼
阿帕蒂尼
免疫疗法
杜瓦卢马布
易普利姆玛
银耳霉素
生物仿制药
无容量
癌症
化疗
结直肠癌
出处
期刊:PubMed
日期:2022-09-20
卷期号:30 (9): 905-911
被引量:2
标识
DOI:10.3760/cma.j.cn501113-20220624-00344
摘要
Targeted and immunotherapy drugs for hepatocellular carcinoma (HCC) have been rapidly developed. Atezolizumab in combination with bevacizumab has been recommended as the first-line standard of care for unresectable or advanced HCC in several national and international guidelines. The combination therapies with sindilizumab and bevacizumab biosimilar, apatinib and carrilizumab, dulvalizumab and tremelimumab are also recommended as first-line standard regimens for advanced HCC in the guideline of Chinese Society of Clinical Oncology. Local therapy combined with targeted drugs (such as sorafenib and lenvatinib) or immune checkpoint inhibitors can significantly improve outcomes. Therefore, some progress has also been made in the study of single-agent or combination regimens as perioperative neoadjuvant therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI